Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CBS | P35520 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431253 | 0.88 | KCNK3 (0.50) | ALDH1A1HTTALOX12MEN1KMT2A | |
| SCHEMBL7441758 | 0.87 | HTT (0.53) | ALDH1A1HTTALOX12KDM4ENPC1 | |
| SCHEMBL7427961 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HTTMEN1KMT2AKDM4E | |
| SCHEMBL15647381 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HTTALOX12CASRMEN1 | |
| SCHEMBL7430635 | 0.80 | CASR (0.46) | ALDH1A1HTTCASRMEN1KMT2A | |
| SCHEMBL13381221 | 0.80 | ALDH1A1 (0.74) | ALDH1A1HTTALOX12CASRMEN1 | |
| SCHEMBL7429896 | 0.80 | ALDH1A1 (0.57) | ALDH1A1HTTALOX12CASRMEN1 | |
| SCHEMBL13406087 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HTTMEN1KMT2ANPC1 | |
| SCHEMBL7434602 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HTTCASRMEN1KMT2A | |
| SCHEMBL7439464 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HTTALOX12CASRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261958-A1 | Combination of Organic Compounds | WEBB RANDY LEE | 2008-10-23 | — | — | US | claimed |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | WEBB RANDY LEE | 2008-05-22 | — | — | US | claimed |
| EP-1863467-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-0318859-A2 | N-substituted mercaptopropanamide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261958-A1 | Combination of Organic Compounds | REN, MME, ACE | ALDH1A1 565/4885HTT 2911/4885ALOX12 1594/4885 |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | MME, REN, ACE | ALDH1A1 1007/4885HTT 1283/4885ALOX12 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.